Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | USP5 | P45974 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384619 | 0.89 | ALDH1A1 (0.48) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL17290508 | 0.80 | ALDH1A1 (0.69) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL20739694 | 0.80 | POLB (0.49) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL20722179 | 0.79 | CYP2D6 (0.43) | ALDH1A1MAPTSMN1; SMN2LMNAUSP2 | |
| SCHEMBL11536910 | 0.78 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL23384529 | 0.77 | HSD11B1 (0.45) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2981180 | 0.76 | ALDH1A1 (0.97) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL26313603 | 0.76 | ALDH1A1 (0.97) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12550106 | 0.76 | ALDH1A1 (0.71) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL5560091 | 0.75 | LMNA (1.00) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2019032631-A1 | OXIME ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032631-A1 | OXIME ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | S1PR1, S1PR3, S1PR2 | ALDH1A1 1798/4885RAB9A 2128/4885NPC1 1835/4885 |
| US-11059784-B2 | Oxime ether compounds | S1PR1, S1PR3, S1PR2 | ALDH1A1 2003/4885RAB9A 2170/4885NPC1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.